PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement

被引：0

作者：

Abou-Alfa, G. ^{[1
]}

Borbath, I. ^{[2
]}

Goyal, L. ^{[3
]}

Lamarca, A. ^{[4
]}

Macarulla, T. ^{[5
]}

Oh, D. ^{[6
]}

Roychowdhury, S. ^{[7
]}

Sadeghi, S. ^{[8
]}

Shroff, R. ^{[9
]}

Soto, J. ^{[10
]}

Pedrioli, G. ^{[11
]}

Fumagalli, L. ^{[11
]}

Dambkowski, C. ^{[10
]}

Javle, M. ^{[12
]}

机构：

[1] Cornell Univ, Mem Sloan Kettering Canc Ctr, Weill Med Coll, New York, NY 10021 USA

[2] Clin Univ St Luc, Brussels, Belgium

[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[4] Christie Natl Hlth Serv Fdn Trust, Manchester, Lancs, England

[5] Hosp Valle De Hebron, Barcelona, Spain

[6] Seoul Natl Univ, Coll Med, Seoul, South Korea

[7] Ohio State Comprehens Canc Ctr, Columbus, OH USA

[8] Univ Calif Los Angeles, David Geffen Sch Med, Santa Monica, CA USA

[9] Univ Arizona, Ctr Canc, Tucson, AZ USA

[10] QED Therapeut Inc, San Francisco, CA USA

[11] Helsinn Healthcare SA, Lugano, Switzerland

[12] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.04.107

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-16

引用

页码：S251 / S252

页数：2

共 50 条

[1] PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement
Abou-Alfa, Ghassan K.
Borbath, Ivan
Goyal, Lipika
Lamarca, Angela
Macarulla, Teresa
Oh, Do-Youn
Roychowdhury, Sameek
Sadeghi, Saeed
Shroff, Rachna T.
Li, Ai
Soto, Jose
Avogadri, Francesca
Dambkowski, Carl L.
Javle, Milind M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements
Abou-Alfa, G. K.
Borbath, I.
Cohn, A. L.
Goyal, L.
Lamarca, A.
Macarulla, T.
Oh, D-Y.
Roychowdhury, S.
Sadeghi, S.
Shroff, R. T.
Howland, M.
Li, A.
Cho, T.
Pande, A.
Javle, M.
ANNALS OF ONCOLOGY, 2020, 31 : S701 - S702
[3] Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.
Javle, Milind M.
Borbath, Ivan
Clarke, Stephen John
Hitre, Erika
Louvet, Christophe
Mercade, Teresa Macarulla
Oh, Do-Youn
Spratlin, Jennifer L.
Valle, Juan W.
Weiss, Karl Heinz
Berman, Craig
Howland, Michael
Ye, Yining
Cho, Terry
Moran, Susan
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[4] Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial
Abou-Alfa, G. K.
Borbath, I.
Clarke, S. J.
Hitre, E.
Louvet, C.
Macarulla, T.
Oh, D-Y.
Spratlin, J. L.
Valle, J. W.
Weiss, K. H.
Berman, C.
Howland, M.
Ye, Y.
Cho, T.
Moran, S.
Javle, M. M.
ANNALS OF ONCOLOGY, 2019, 30
[5] PROOF 301: Results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion/rearrangement.
Abou-Alfa, Ghassan K.
Borbath, Ivan
Roychowdhury, Sameek
Goyal, Lipika
Lamarca, Angela
Macarulla, Teresa
Shroff, Rachna T.
Oh, Do-Youn
Javle, Milind M.
Tamas, Catalin
Savastano, David M.
Van Veenhuyzen, David Friedrich
Xu, Cindy
Solanas, Jacki
Freas, Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 516 - 516
[6] Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial
Javle, M.
Borbath, I.
Clarke, S.
Hitre, E.
Louver, C.
Macarulla, T.
Oh, D.
Spratlin, J.
Valee, J.
Weiss, K.
Berman, C.
Howland, M.
Ye, Y.
Cho, T.
Moran, S.
Abou-Alfa, C.
ANNALS OF ONCOLOGY, 2019, 30 : 62 - 62
[7] Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial
Makawita, Shalini
Abou-Alfa, Ghassan K.
Roychowdhury, Sameek
Sadeghi, Saeed
Borbath, Ivan
Goyal, Lipika
Cohn, Allen
Lamarca, Angela
Oh, Do-Youn
Macarulla, Teresa
Shroff, Rachna T.
Howland, Michael
Li, Ai
Cho, Terry
Pande, Amit
Javle, Milind
FUTURE ONCOLOGY, 2020, 16 (30) : 2375 - 2384
[8] Infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: phase 3 PROOF trial
Abou-Alfa, G.
Borbath, I.
Cohn, A.
Goyal, L.
Lamarca, A.
Macarulla, T.
Oh, D.
Roychowdhury, S.
Sadeghi, S.
Shroff, R.
Howland, M.
Li, A.
Cho, T.
Pande, A.
Javle, M.
ANNALS OF ONCOLOGY, 2020, 31 : S136 - S137
[9] FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine plus cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement
Vogel, A.
Valle, J. W.
van Cutsem, E.
Rimassa, L.
Furuse, J.
Ioka, T.
Melisi, D.
Macarulla, T.
Bridgewater, J.
Wasan, H. S.
Borad, M. J.
Lihou, C. F.
Zhen, H.
Feliz, L.
Asatiani, E.
Jiang, P.
Bekaii-Saab, T. S.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 122 - 122
[10] FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine plus cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement
Bekaii-Saab, T.
Valle, J.
Van Cutsem, E.
Rimassa, L.
Furuse, J.
Ioka, T.
Macarulla, T.
Bridgewater, J.
Wasan, H.
Borad, M.
Vogel, A.
Lihou, C.
Zhen, H.
Jiang, P.
Langmuir, P.
Melisi, D.
ANNALS OF ONCOLOGY, 2021, 32 : S137 - S137

← 1 2 3 4 5 →